Navigation Links
Cell Therapeutics Reaches Agreement to Reacquire Rights to Two Anti-Cancer Compounds
Date:1/13/2014

ique structural and physiochemical properties. Unlike related compounds, PIXUVRI forms stable DNA adducts and in preclinical models has superior anti-lymphoma activity compared to related compounds. PIXUVRI was structurally designed so that it cannot bind iron and perpetuate oxygen radical production or form a long-lived hydroxyl metabolite -- both of which are the putative mechanisms for anthracycline induced acute and chronic cardiotoxicity.  These novel pharmacologic properties allow PIXUVRI to be administered to patients with near maximal lifetime exposure to anthracyclines without unacceptable rates of cardiotoxicity.

In May 2012, the European Commission (EC) granted conditional marketing authorization for PIXUVRI as a monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive NHL. The benefit of PIXUVRI treatment has not been established in patients when used as fifth line or greater chemotherapy in patients who are refractory to last therapy. The Summary of Product Characteristics (SmPC) has the full prescribing information, including the safety and efficacy profile of PIXUVRI in the approved indication. The SmPC is available at www.pixuvri.eu.

CTI is currently accruing patients into a Phase 3 trial comparing PIXUVRI and rituximab with gemcitabine and rituximab in the setting of aggressive B-cell NHL. PIXUVRI does not have marketing approval in the United States.

About Opaxio

Opaxio™ (paclitaxel poliglumex) is an investigational, biologically-enhanced chemotherapeutic that links paclitaxel, the active ingredient in Taxol®, to a biodegradable polyglutamate polymer, which results in a new chemical entity. When bound to the polymer, paclitaxel is inactive, potentially sparing normal tissue's exposure to high levels of paclitaxel and its associated toxicities. Blood vessels in tumor tis
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Sorrento Therapeutics to Present at the Biotech Showcase 2014 and the 7th Annual OneMed Forum SF2014 in San Francisco
2. PhaseRx Appoints Michael Houston, Ph.D., Vice President, Therapeutics Development
3. ImmunoCellular Therapeutics Issues Shareholder Letter Providing Update on ICT-107 Program in Newly Diagnosed Glioblastoma
4. Altheus Therapeutics announces completed enrollment of ZA201, a Phase 2 clinical trial of Zoenasa for distal ulcerative colitis
5. Liver Diseases Therapeutics Market (Chemotherapy, Anti-Virals, Vaccines, Targeted Therapy and Immunosuppressants) - Global Industry Analysis, Size, Share, Trends and Forecast, 2012 - 2018
6. Nektar Therapeutics President and CEO, Howard W. Robin, To Present at the 32nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA
7. Flexion Therapeutics Files Registration Statement for Proposed Initial Public Offering
8. G1 Therapeutics to Present at Biotech Showcase 2014
9. Daiichi Sankyo, Virtici and Celdara Medical Announce Collaboration to Identify and Progress High Potential Therapeutics
10. Mast Therapeutics Provides Enrollment Update On Phase 3 "EPIC" Study Of MST-188
11. Revamped Therapies Preventing Visual Impairment Primed to Revolutionize US Retinal Therapeutics Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... and Delaware , United ... (ASX: IVX; "Company" or "Invion"), is pleased to announce that ... securities to an institutional investor in the United ... proceeds of approximately A$1.001 million ("Placement") by the issue of ... of $0.014 per share. The Company has ...
(Date:9/1/2015)... , Sept. 1, 2015 Nevro Corp. ... that is providing innovative evidence-based solutions for the treatment ... submitted its preliminary response to the Patent Trial and ... inter partes review (IPR), filed by a unit ... claims in U.S. Patent No. 8,359,102 (the ,102 patent). The ...
(Date:9/1/2015)... Calif. , Sept. 1, 2015 ... biopharmaceutical company focused on gastrointestinal and cardio-renal diseases, ... termination of the option and license agreement for ... 2015. There was no payment associated with termination ... February 2014, Ardelyx and Sanofi entered into an ...
Breaking Medicine Technology:Invion Announces Private Placement to US Institutional Investor 2Invion Announces Private Placement to US Institutional Investor 3Nevro Announces Submission of Preliminary Response to the Patent Trial and Appeals Board 2Ardelyx Regains NaP2b Program from Sanofi 2Ardelyx Regains NaP2b Program from Sanofi 3
... ... convenience to hospitals, reduce costs and lead to more efficient operating ... that once hospitals have converted to CPT, they will never convert ... using custom packs, but have also come to realise the true ...
... INDIANAPOLIS, Dec. 7 Roche Diagnostics announced today the opening ... as part of an initiative to make state-of-the-art training on ... the west and east coasts. Roche has an existing training ... open an additional facility in New Jersey in 2010. , ...
Cached Medicine Technology:Frost & Sullivan: Western European Markets Confirm Undisputed Convenience and Cost Benefit of Custom Procedure Trays 2Frost & Sullivan: Western European Markets Confirm Undisputed Convenience and Cost Benefit of Custom Procedure Trays 3Frost & Sullivan: Western European Markets Confirm Undisputed Convenience and Cost Benefit of Custom Procedure Trays 4Roche Diagnostics Opens State-of-the-Art Training Center in California 2
(Date:9/2/2015)... ... September 02, 2015 , ... “ G-Hold ” was featured on ... technology products available to consumers. Amanda Forstrom, a technology expert and special reporter for ... people to comfortably hold a tablet while reducing the likelihood of it dropping. , ...
(Date:9/2/2015)... ... September 02, 2015 , ... Please ... Aneurysm Awareness Month , which was established by the Foundation in 2007 with ... education, and helping fund more research remains our top priority,” commented Christine Buckley, ...
(Date:9/2/2015)... SC (PRWEB) , ... September 02, 2015 , ... ... announced today that he is now certified in “Systema”: a Russian martial art system ... aspects of life. , Systema , which dates back to the 10th ...
(Date:9/2/2015)... ... September 02, 2015 , ... Traveling to the Caribbean can be an ... flora and fauna. , Lifestyle Holidays Vacation Club knows that Puerto ... travelers experience that much better, Lifestyle Holidays Vacation Club has put together its list ...
(Date:9/1/2015)... ... September 01, 2015 , ... For many men, the first thing they notice when they go ... to wear a looser fitting shirt with a collar that doesn’t close against the skin, ... their collar and skin all day because it’s uncomfortable. Now men in suits will ...
Breaking Medicine News(10 mins):Health News:Comfortably Hold a Tablet with G-Hold Hands Free Tablet Holder 2Health News:September Celebrated as Brain Aneurysm Awareness Month 2Health News:Dr. Robert G. Schwartz Achieves Certification in Russian Martial Art “Systema” and Focuses on Integrating Techniques & Principles into Health Care Delivery 2Health News:Dr. Robert G. Schwartz Achieves Certification in Russian Martial Art “Systema” and Focuses on Integrating Techniques & Principles into Health Care Delivery 3Health News:Lifestyle Holidays Vacation Club Lists 3 Things to Consider When On a Puerto Plata Vacation 2Health News:Lifestyle Holidays Vacation Club Lists 3 Things to Consider When On a Puerto Plata Vacation 3Health News:Getting Rid of Double Chins: New FDA Approved Kybella Treatment Proving Very Popular Among Professional Men at Crutchfield Dermatology 2
... October 5, 2011 The Merck Childhood Asthma ... million in funding to implement the Community Healthcare ... partnership in five non-profit, Federally Qualified Health Centers. ... designed to demonstrate how asthma management tools proven ...
... (October 4, 2011)In a new study led by Fox ... have found that Gleason scores determined by pathologists at ... of recurrence than Gleason scores from referring institutions. ... Meeting of the American Society for Radiation Oncology on ...
... of Adelaide shows the parents of women with polycystic ovary syndrome ... PCOS is a hormonal disorder affecting about 10% of women ... endocrine disorders in women and a leading cause of infertility. ... to have any form of cardiovascular disease, and almost twice as ...
... TUESDAY, Oct. 4 (HealthDay News) -- Heart patients who have stenting ... they are released the same day as if they are sent ... "[Discharging patients the same day] wasn,t associated with any increased risk ... study appearing in the Oct. 5 issue of the Journal ...
... , WEDNESDAY, Oct. 5 (HealthDay News) -- Three hours of ... risk by 22 percent, a new study suggests. The ... 38 percent of that decreased risk was due to the ... high-density lipoprotein (HDL) cholesterol. The findings were published Oct. ...
... TUESDAY, Oct. 4 (HealthDay News) -- ,A common structural variation ... able to remember details of past events and to distinguish ... have imagined, scientists report. The study included 53 healthy ... Participants who lacked a fold at the front of the ...
Cached Medicine News:Health News:Childhood asthma non-profit invests millions in health centers to help children better manage asthma 2Health News:Childhood asthma non-profit invests millions in health centers to help children better manage asthma 3Health News:Fox Chase Gleason scores better predict prostate cancer's recurrence after radiation 2Health News:Fox Chase Gleason scores better predict prostate cancer's recurrence after radiation 3Health News:Overnight Stay May Not Be Necessary for Stenting: Study 2Health News:Overnight Stay May Not Be Necessary for Stenting: Study 3Health News:MRI Study Unfolds Clues to Memory 2
VISCO SHIELD Viscoelastic. Complete with 23g x 7/8" Thin Wall Cannula....
Interchangeable design allows you to select a single handpiece and change tips during the procedure. Universal connector. Disassembles for easy cleaning. Tips can rotate 360 degrees to re-orient port...
Interchangeable design allows you to select a single handpiece and change tips during the procedure. Universal connector. Disassembles for easy cleaning. Tips can rotate 360 degrees to re-orient port...
Interchangeable design allows you to select a single handpiece and change tips during the procedure. Universal connector. Disassembles for easy cleaning. Tips can rotate 360 degrees to re-orient port...
Medicine Products: